During the past decade, Toronto Urology Clinical Study Group conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Toronto Urology Clinical Study Group" are "Hypogonadism" (1 trials) and "Overactive Bladder" (1 trials). Many other conditions were trialed in "Toronto Urology Clinical Study Group" in a lesser frequency.

Most popular intervention types in "Toronto Urology Clinical Study Group" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Fesoterodine 4mg" (1 trials), "Fesoterodine 8mg" (1 trials), "NATESTO Testosterone Nasal Gel" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Toronto Urology Clinical Study Group" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Toronto Urology Clinical Study Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Toronto Urology Clinical Study Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Toronto Urology Clinical Study Group, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".